Quality-by-design-based microemulsion of disulfiram for repurposing in melanoma and breast cancer therapy.

IF 3 Q2 PHARMACOLOGY & PHARMACY
Therapeutic delivery Pub Date : 2024-01-01 Epub Date: 2024-07-01 DOI:10.1080/20415990.2024.2363136
Debadatta Mohapatra, Prakash Ch Senapati, Shantibhusan Senapati, Vivek Pandey, Pawan K Dubey, Sanjay Singh, Alakh N Sahu
{"title":"Quality-by-design-based microemulsion of disulfiram for repurposing in melanoma and breast cancer therapy.","authors":"Debadatta Mohapatra, Prakash Ch Senapati, Shantibhusan Senapati, Vivek Pandey, Pawan K Dubey, Sanjay Singh, Alakh N Sahu","doi":"10.1080/20415990.2024.2363136","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> The current study aims to develop and optimize microemulsions (ME) through Quality-by-Design (QbD) approach to improve the aqueous solubility and dissolution of poorly water-soluble drug disulfiram (DSF) for repurposing in melanoma and breast cancer therapy.<b>Materials & methods:</b> The ME was formulated using Cinnamon oil & Tween<sup>®</sup> 80, statistically optimized using a D-optimal mixture design-based QbD approach to develop the best ME with low vesicular size (Z<sub>avg</sub>) and polydispersity index (PDI).<b>Results:</b> The DSF-loaded optimized stable ME showed enhanced dissolution, <i>in-vitro</i> cytotoxicity and improved cellular uptake in B16F10 and MCF-7 cell lines compared with their unformulated free DSF.<b>Conclusion:</b> Our investigations suggested the potential of the statistically designed DSF-loaded optimized ME for repurposing melanoma and breast cancer therapy.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"521-544"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2024.2363136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The current study aims to develop and optimize microemulsions (ME) through Quality-by-Design (QbD) approach to improve the aqueous solubility and dissolution of poorly water-soluble drug disulfiram (DSF) for repurposing in melanoma and breast cancer therapy.Materials & methods: The ME was formulated using Cinnamon oil & Tween® 80, statistically optimized using a D-optimal mixture design-based QbD approach to develop the best ME with low vesicular size (Zavg) and polydispersity index (PDI).Results: The DSF-loaded optimized stable ME showed enhanced dissolution, in-vitro cytotoxicity and improved cellular uptake in B16F10 and MCF-7 cell lines compared with their unformulated free DSF.Conclusion: Our investigations suggested the potential of the statistically designed DSF-loaded optimized ME for repurposing melanoma and breast cancer therapy.

基于质量设计的双硫仑微乳剂用于黑色素瘤和乳腺癌治疗的再利用。
目的:本研究旨在通过质量源于设计(QbD)方法开发和优化微乳剂(ME),以改善水溶性差的药物双硫仑(DSF)的水溶性和溶解性,从而重新用于黑色素瘤和乳腺癌的治疗。材料与方法:使用肉桂油和吐温®80配制ME,并采用基于D-最佳混合物设计的QbD方法进行统计优化,以开发出具有低囊泡尺寸(Zavg)和多分散指数(PDI)的最佳ME。结果:与未配制的游离 DSF 相比,负载 DSF 的优化稳定 ME 在 B16F10 和 MCF-7 细胞系中显示出更强的溶解性、体外细胞毒性和细胞摄取能力。结论我们的研究表明,经过统计设计的负载 DSF 的优化 ME 有潜力重新用于黑色素瘤和乳腺癌的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic delivery
Therapeutic delivery PHARMACOLOGY & PHARMACY-
CiteScore
5.50
自引率
0.00%
发文量
25
期刊介绍: Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信